Vanda Pharmaceuticals Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Vanda Pharmaceuticalshan disminuido a un ritmo medio anual de -28.4%, mientras que en la industria Biotechs los ingresos han sido de growing a 17.4% anuales. Los ingresos han sido growing a un ritmo medio de 4.7% al año. Vanda Pharmaceuticals La rentabilidad de los fondos propios de la empresa es de 2.2% y sus márgenes netos son de 5.6%.

Información clave

-37.5%

Tasa de crecimiento de los beneficios

-38.6%

Tasa de crecimiento del BPA

Crecimiento de la industria Biotechs	17.0%
Tasa de crecimiento de los ingresos	2.4%
Rentabilidad financiera	0.5%
Margen neto	1.3%
Última actualización de beneficios	31 Dec 2023

Actualizaciones de resultados anteriores recientes

Vanda Pharmaceuticals' (NASDAQ:VNDA) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Feb 15

Recent updates

Vanda Pharmaceuticals: Fanapt Bipolar Win Doesn't Change Much

Apr 05

Vanda Pharmaceuticals' (NASDAQ:VNDA) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Feb 15

Vanda Pharmaceuticals' Portfolio Likely Has Upside From 2024 Approvals, Underpinned By Cash

Feb 13

Vanda Pharmaceuticals Inc.'s (NASDAQ:VNDA) Low P/S No Reason For Excitement

Feb 10

News Flash: One Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Analyst Has Been Trimming Their Revenue Forecasts

Nov 11

One Forecaster Is Now More Bearish On Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Than They Used To Be

May 12

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero Vanda Pharmaceuticals. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

NasdaqGM:VNDA Ingresos, gastos y beneficios (USD Millions)
Fecha	Ingresos	Beneficios	Gastos G+A	Gastos de I+D
31 Dec 23	193	3	113	77
30 Sep 23	212	12	122	71
30 Jun 23	238	15	127	79
31 Mar 23	257	16	132	84
31 Dec 22	254	6	136	86
30 Sep 22	258	6	137	87
30 Jun 22	263	11	140	81
31 Mar 22	266	18	135	80
31 Dec 21	269	33	124	75
30 Sep 21	268	34	126	71
30 Jun 21	259	32	128	64
31 Mar 21	253	32	133	56
31 Dec 20	248	23	141	56
30 Sep 20	241	19	142	54
30 Jun 20	241	114	138	53
31 Mar 20	237	117	136	51
31 Dec 19	227	116	130	49
30 Sep 19	219	122	118	48
30 Jun 19	209	28	113	49
31 Mar 19	197	22	110	47
31 Dec 18	193	25	106	44
30 Sep 18	184	13	112	41
30 Jun 18	177	1	117	40
31 Mar 18	171	-5	120	37
31 Dec 17	165	-16	124	39
30 Sep 17	159	-14	117	36
30 Jun 17	156	-10	107	33
31 Mar 17	150	-13	101	32
31 Dec 16	146	-18	100	29
30 Sep 16	140	-32	105	30
30 Jun 16	129	-41	101	33
31 Mar 16	121	-42	95	32
31 Dec 15	110	-40	85	29
30 Sep 15	93	45	73	25
30 Jun 15	80	53	66	19
31 Mar 15	63	36	76	16
31 Dec 14	50	20	85	19
30 Sep 14	44	-57	77	21
30 Jun 14	37	-61	72	25
31 Mar 14	35	-43	49	28
31 Dec 13	34	-21	25	29
30 Sep 13	33	-20	18	33
30 Jun 13	33	-20	15	35

Ingresos de calidad: VNDA tiene un alto nivel de ganancias no monetarias.

Margen de beneficios creciente: VNDALos actuales márgenes de beneficio netos de (1.3%) son inferiores a los del año pasado (2.5%).

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: VNDALos beneficios de la empresa han disminuido en 28.4% al año en los últimos 5 años.

Acelerando crecimiento: VNDA's ha tenido un crecimiento negativo de los beneficios en el último año, por lo que no puede compararse con su media de 5 años.

Beneficios vs. Industria: VNDA tuvo un crecimiento negativo de los beneficios (-60%) durante el año pasado, lo que dificulta la comparación con la media del sector Biotechs (-8.1%).

Rentabilidad financiera

Alta ROE: El Retorno sobre el capital de VNDA (2.2%) se considera bajo.

Rentabilidad económica

Rendimiento del capital invertido

Descubre empresas con buenos resultados en el pasado

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Vanda Pharmaceuticals Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Información clave

Actualizaciones de resultados anteriores recientes

Vanda Pharmaceuticals' (NASDAQ:VNDA) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Vanda Pharmaceuticals Inc. to Report Q4, 2023 Results on Feb 07, 2024

Third quarter 2023 earnings released: EPS: US$0.002 (vs US$0.058 in 3Q 2022)

Vanda Pharmaceuticals Inc. to Report Q3, 2023 Results on Nov 08, 2023

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Recent updates

Future Pak, Ltd. submits a proposal to acquire Vanda Pharmaceuticals Inc. (NasdaqGM:VNDA) from The Vanguard Group, Inc., State Street Corporation (NYSE:STT), BlackRock, Inc. (NYSE:BLK), Dimensional Fund Advisors LP and others for approximately $450 million.

Future Pak, Ltd. submits a proposal to acquire Vanda Pharmaceuticals Inc. (NasdaqGM:VNDA) from The Vanguard Group, Inc., State Street Corporation (NYSE:STT), BlackRock, Inc. (NYSE:BLK), Dimensional Fund Advisors LP and others for approximately $450 million.

Consensus EPS estimates fall from profit to US$0.06 loss, revenue upgraded

Vanda Pharmaceuticals: Fanapt Bipolar Win Doesn't Change Much

New minor risk - Share price stability

Vanda Pharmaceuticals' Fanapt (Iloperidone) Receives U.S. FDA Approval for the Acute Treatment of Bipolar I Disorder

Insider recently sold US$73k worth of stock

Founder notifies of intention to sell stock

Vanda Pharmaceuticals Announces FDA Update for Supplemental NDA for HETLIOZ in the Treatment of Insomnia

Vanda Pharmaceuticals' (NASDAQ:VNDA) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Consensus revenue estimates increase by 27%

Vanda Pharmaceuticals' Portfolio Likely Has Upside From 2024 Approvals, Underpinned By Cash

Vanda Pharmaceuticals Inc.'s (NASDAQ:VNDA) Low P/S No Reason For Excitement

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Vanda Pharmaceuticals Announces FDA Update for supplemental NDA for HETLIOZ® in the Treatment of Insomnia

Vanda Pharmaceuticals Inc. to Report Q4, 2023 Results on Feb 07, 2024

Vanda Pharmaceuticals Inc. Announces U.S. Food and Drug Administration Approval for VTR-297 for the Treatment of Onychomycosis

Vanda Pharmaceuticals Inc. Receives FDA Approval to Proceed with Investigational New Drug VCA-894A, a Novel Antisense Oligonucleotide Candidate for the Treatment of Charcot-Marie-Tooth Disease, Type 2S

Now 21% undervalued after recent price drop

Vanda Pharmaceuticals Inc. Announces U.S. Food and Drug Administration Accepts New Drug Application for Tradipitant for the Treatment of Gastroparesis

Now 21% undervalued after recent price drop

News Flash: One Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Analyst Has Been Trimming Their Revenue Forecasts

Third quarter 2023 earnings released: EPS: US$0.002 (vs US$0.058 in 3Q 2022)

Vanda Pharmaceuticals Inc. to Report Q3, 2023 Results on Nov 08, 2023

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Vanda Pharmaceuticals Inc. to Report Q2, 2023 Results on Jul 27, 2023

Senior VP recently sold US$96k worth of stock

Senior VP notifies of intention to sell stock

Vanda Pharmaceuticals Inc Reports Results from a Phase III study of Tradipitant in Motion Sickness

One Forecaster Is Now More Bearish On Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Than They Used To Be

Vanda Pharmaceuticals Inc. Responds to the Ruling in its Hetlioz(R) Abbreviated New Drug Application Appeal

First quarter 2023 earnings released: EPS: US$0.057 (vs US$0.12 loss in 1Q 2022)

Insider recently sold US$105k worth of stock

Founder notifies of intention to sell stock

Insufficient new directors

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Vanda Pharmaceuticals Inc. to Report Q4, 2022 Results on Feb 08, 2023

Vanda Pharmaceuticals Inc. Announces Fanapt® Shown to be Effective in Bipolar I Disorder in Phase III Clinical Study

Senior VP recently sold US$56k worth of stock

Vanda Pharmaceuticals Provides an Update to HETLIOZ ANDA Litigation Appeal: Federal Circuit Grants Motion to Temporarily Enjoin Generic Launch

Now 45% undervalued after recent price drop

Investor sentiment deteriorated over the past week

Founder notifies of intention to sell stock

Vvanda Pharmaceuticals Inc. Reports Results in A Phase II Clinical Study of Vqw-765 in the Treatment of Acute Performance Anxiety

Price target increased to US$11.00

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Vanda Pharmaceuticals Inc. Revises Financial Guidance for the Year 2022

Vanda Pharmaceuticals Inc. to Report Q3, 2022 Results on Nov 02, 2022

Now 20% undervalued after recent price drop

Robbins Geller Rudman & Dowd LLP Announces Proposed Settlement in the Vanda Pharmaceuticals Inc. Securities Litigation

Vanda Pharmaceuticals: What The Recent Partnership Entails

Vanda Pharma, OliPass collaborate to develop oligonucleotide-based therapeutics

Vanda Pharmaceuticals Inc. Announces Notice of Opportunity for an FDA Hearing on the sNDA for HETLIOZ in Jet Lag Disorder

Consensus EPS estimates increase by 11%

Senior VP recently sold US$86k worth of stock

Consensus forecasts updated

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Vanda Pharmaceuticals Inc. Provides Revenue Guidance for the Full Year 2022

Vanda Pharmaceuticals Q2 Earnings Preview

Vanda Pharmaceuticals Inc. to Report Q2, 2022 Results on Aug 03, 2022

Lead Independent Director notifies of intention to sell stock

Vanda Pharmaceuticals: Strong Pipeline Developments To Power Long-Term Upside

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Vanda Pharmaceuticals Inc. Provides Financial Guidance for the Year 2022

Price target decreased to US$12.00

Vanda Pharmaceuticals Inc., Annual General Meeting, Jun 16, 2022

Vanda: A Dual Growth And Value Player

Consensus forecasts updated

Desglose de ingresos y gastos
Beta